Pomalidomide-PEG4-azide is primarily utilized in the development of antibody-drug conjugates (ADCs) and targeted cancer therapies. Its structure allows for the conjugation of pomalidomide, an immunomodulatory agent, to antibodies or other targeting molecules via the PEG4-azide linker. This enables precise delivery of the drug to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It is also employed in proteolysis-targeting chimeras (PROTACs) to degrade specific proteins involved in disease pathways. Additionally, the compound is used in research to study protein-protein interactions and cellular signaling mechanisms, particularly in the context of cancer and immune modulation. Its versatility makes it a valuable tool in both therapeutic development and biomedical research.